JPWO2021035194A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021035194A5
JPWO2021035194A5 JP2022511201A JP2022511201A JPWO2021035194A5 JP WO2021035194 A5 JPWO2021035194 A5 JP WO2021035194A5 JP 2022511201 A JP2022511201 A JP 2022511201A JP 2022511201 A JP2022511201 A JP 2022511201A JP WO2021035194 A5 JPWO2021035194 A5 JP WO2021035194A5
Authority
JP
Japan
Prior art keywords
cells
inhibitor
ezh2
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022511201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545467A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047537 external-priority patent/WO2021035194A1/en
Publication of JP2022545467A publication Critical patent/JP2022545467A/ja
Publication of JPWO2021035194A5 publication Critical patent/JPWO2021035194A5/ja
Pending legal-status Critical Current

Links

JP2022511201A 2019-08-22 2020-08-21 T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法 Pending JP2022545467A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962890607P 2019-08-22 2019-08-22
US62/890,607 2019-08-22
US202063024502P 2020-05-13 2020-05-13
US63/024,502 2020-05-13
US202063037584P 2020-06-10 2020-06-10
US63/037,584 2020-06-10
PCT/US2020/047537 WO2021035194A1 (en) 2019-08-22 2020-08-21 Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods

Publications (2)

Publication Number Publication Date
JP2022545467A JP2022545467A (ja) 2022-10-27
JPWO2021035194A5 true JPWO2021035194A5 (ko) 2023-08-28

Family

ID=72432997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511201A Pending JP2022545467A (ja) 2019-08-22 2020-08-21 T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法

Country Status (6)

Country Link
US (1) US20220298222A1 (ko)
EP (1) EP4017527A1 (ko)
JP (1) JP2022545467A (ko)
KR (1) KR20220066892A (ko)
CN (1) CN114555112A (ko)
WO (1) WO2021035194A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
AU6467796A (en) 1996-04-24 1997-05-15 Claude Fell Cell separation system for biological fluids like blood
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
EP1033411B1 (en) 1996-06-04 2006-02-22 University of Utah Research Foundation Fluorescent donor-acceptor pair
US6420108B2 (en) 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
JP2001519143A (ja) 1997-10-02 2001-10-23 スノル・モレキュラー・コーポレーション 可溶性の一本鎖t細胞レセプタータンパク質
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
JP2002515243A (ja) 1998-05-19 2002-05-28 アヴィデックス リミテッド 多価t細胞受容体複合体
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
DE69919029T2 (de) 1998-12-24 2005-09-08 Biosafe S.A. Vorrichtung zur bluttrennung, insbesondere zur konzentrierung von hematopoietischen stammzellen
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
ES2267803T3 (es) 2000-08-11 2007-03-16 University Of Utah Research Foundation Sondas de oligonucleotidos marcados individuales.
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
JP4317940B2 (ja) 2001-08-31 2009-08-19 イミュノコア・リミテッド 物質
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
ITCZ20020002A1 (it) 2002-04-11 2003-10-13 Parco Scient E Tecnologico Del Dispositivo e metodo per il rilevamento simultaneo di differenti anticorpi e antigeni in campioni clinici, alimentari ed ambientali
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
CA2567814C (en) 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
DK1791865T3 (da) 2004-06-29 2010-11-01 Immunocore Ltd Celler der udtrykker en modificeret T-cellerecptor
EP1893253B1 (en) 2005-03-23 2010-05-19 Biosafe S.A. Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine
ES2663323T3 (es) 2007-03-30 2018-04-12 Memorial Sloan-Kettering Cancer Center Expresión constitutiva de ligandos coestimuladores en linfocitos T transferidos de manera adoptiva
ES2374863T3 (es) 2007-12-07 2012-02-22 Miltenyi Biotec Gmbh Centrífuga para separar una muestra en por lo menos dos componentes.
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
EP4049674A1 (en) 2009-11-03 2022-08-31 City of Hope Truncated epidermal growth factor receptor (egfrt) for transduced t cell selection
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
MX347078B (es) 2010-12-09 2017-04-10 Univ Pennsylvania Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換6,5−縮合二環式ヘテロアリール化合物
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
SG193956A1 (en) 2011-04-01 2013-11-29 Sloan Kettering Inst Cancer T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
AU2012315566A1 (en) 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
CA2854447A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
MX359234B (es) 2011-11-11 2018-09-20 Hutchinson Fred Cancer Res Inmunoterapia de celulas t objetivadas en ciclina a1 para cancer.
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP4190777A1 (en) 2012-04-13 2023-06-07 Epizyme, Inc. Hbr salt form for ezh2 inhibition
AU2013256159B2 (en) 2012-05-03 2018-08-09 Fred Hutchinson Cancer Center Enhanced affinity T cell receptors and methods for making the same
SG10201701339RA (en) 2012-08-20 2017-03-30 Seattle Children S Hospital Dba Seattle Children S Res Inst Method and compositions for cellular immunotherapy
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CA2888021A1 (en) 2012-10-15 2014-04-24 Epizyme, Inc. Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders
EP2908843B1 (en) 2012-11-19 2019-09-04 Agency For Science, Technology And Research Treating cancer
US9895390B2 (en) 2012-12-10 2018-02-20 Children's Medical Center Corporation Methods and assays for combination treatment of cancer
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP6373973B2 (ja) 2013-04-30 2018-08-15 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Zesteホモログ2エンハンサー阻害剤
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MY179802A (en) 2013-10-16 2020-11-16 Eisai R&D Man Co Ltd Hydrochloride salt form for ezh2 inhibition
SG11201607006TA (en) 2014-03-17 2016-10-28 Daiichi Sankyo Co Ltd 1,3-benzodioxole derivative
MX2016012021A (es) 2014-03-19 2017-04-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
IL292038A (en) 2014-04-23 2022-06-01 Juno Therapeutics Inc Methods for enriching and producing immune cell populations for stress treatment
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2965729A1 (en) 2014-10-28 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
CA2966538A1 (en) 2014-11-05 2016-05-12 Juno Therapeutics, Inc. Methods for transduction and cell processing
CN113388036A (zh) 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
EP3227432B1 (en) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
IL252621B1 (en) 2014-12-05 2024-02-01 Memorial Sloan Kettering Cancer Center G-protein receptor-directed chimeric antigen receptors and their use
IL285101B2 (en) 2014-12-05 2024-03-01 Memorial Sloan Kettering Cancer Center G protein-coupled receptor-directed antibodies and methods of use
WO2016130396A1 (en) 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2016201328A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
CN107847497B (zh) 2015-07-30 2021-03-30 第一三共株式会社 用于成人t细胞白血病/淋巴瘤的治疗和/或预防剂
US20180221362A1 (en) 2015-08-03 2018-08-09 Constellation Pharmaceuticals, Inc. Ezh2 inhibitors and modulation of regulatory t-cell function
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
US11624068B2 (en) * 2016-07-15 2023-04-11 Tufts Medical Center, Inc. Compositions and methods for improving immune system function
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
TW201831181A (zh) 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療htlv-1相關脊髓病之醫藥組成物
US20230201212A1 (en) 2017-06-13 2023-06-29 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
US11459315B2 (en) 2017-11-09 2022-10-04 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Similar Documents

Publication Publication Date Title
Park et al. Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells
US20200016202A1 (en) Modulation of novel immune checkpoint targets
US20210155932A1 (en) Compositions and methods to treat cancer
US11685782B2 (en) Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
Zhang et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells
Jin et al. MicroRNA-31 suppresses medulloblastoma cell growth by inhibiting DNA replication through minichromosome maintenance 2
US20210254097A1 (en) Engineering of immune cells for ex vivo cell therapy applications
Lin et al. Functional differences and similarities in activated peripheral blood mononuclear cells by lipopolysaccharide or phytohemagglutinin stimulation between human and cynomolgus monkeys
Andersson et al. Survivin controls biogenesis of microRNA in smokers: a link to pathogenesis of rheumatoid arthritis
Jiang et al. Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction
JP2020535119A5 (ko)
JP2022179694A (ja) Krasバリアントがん患者の免疫ベースの処置
EP3704273A1 (de) Verfahren zur bestimmung des ansprechens einer malignen erkrankung auf eine immuntherapie
Garrido et al. Circumvention of confluence‐dependent resistance in a human multi‐drug‐resistant colon‐cancer cell line
JPWO2021035194A5 (ko)
CN113372444A (zh) 通过抑制胞外核苷酸酶和抗体-介导靶向吞噬预防或逆转t-细胞衰竭的组合物与用途
US20220298222A1 (en) Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
JP6833037B2 (ja) 脂肪肝の診断または治療のためのロイシンジッパータンパク質の用途
Masamoto et al. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
Herbert et al. Z-DNA enhances immunotherapy by triggering death of inflammatory cancer-associated fibroblasts
AU2021357805A9 (en) Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
US20240042028A1 (en) Methods of nk cell engineering to enhance tumor targeting
JP7410480B2 (ja) がんにおける融合遺伝子
Zhang et al. INAUGURAL ARTICLE by a Recently Elected Academy Member: Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown
EP3937986A1 (en) Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage